Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EBITDA (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed EBITDA for 10 consecutive years, with -$47.1 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 14.08% to -$47.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$192.0 million, a 27.68% increase, with the full-year FY2025 number at -$202.7 million, up 23.45% from a year prior.
  • EBITDA was -$47.1 million for Q4 2025 at Rhythm Pharmaceuticals, up from -$52.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$34.4 million in Q1 2021 to a low of -$139.9 million in Q1 2024.
  • A 5-year average of -$49.6 million and a median of -$44.8 million in 2021 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 166.29% in 2024, then surged 66.4% in 2025.
  • Rhythm Pharmaceuticals' EBITDA stood at -$51.0 million in 2021, then grew by 17.43% to -$42.1 million in 2022, then increased by 1.99% to -$41.3 million in 2023, then rose by 0.02% to -$41.3 million in 2024, then dropped by 14.08% to -$47.1 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's EBITDA are -$47.1 million (Q4 2025), -$52.7 million (Q3 2025), and -$45.3 million (Q2 2025).